Skip to main content
49°
Clear
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Business Service Directory
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Novartis AG Common Stock
(NY:
NVS
)
124.12
-3.58 (-2.80%)
Official Closing Price
Updated: 7:00 PM EDT, Sep 12, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novartis AG Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
48
49
Next >
This Applied Materials Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
September 12, 2025
Via
Benzinga
Google DeepMind Chief Eyes Radical AI-Powered Shift In Drug Discovery Speed — Eli Lilly, Novartis Are Already Onboard
September 12, 2025
Via
Stocktwits
Why Is Avidity Biosciences Stock Down 20% Pre-market Today?
September 11, 2025
Via
Stocktwits
Wall Street Cheers Nebius-Microsoft Megadeal While Apple Misses the Mark
September 10, 2025
U.S. markets closed higher on Tuesday, buoyed by fresh labor data signaling a cooling job market—potentially paving the way for Fed rate cuts. Nebius soared nearly 50% on a multibillion-dollar AI-cloud...
Via
Chartmill
Topics
Economy
Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
September 09, 2025
Trump's policies have sparked a $350B investment surge in US biotech, creating job & revenue opportunities. Investors can track with XBI or IBB ETFs and consider JNJ, NVS, LLY, AZN, BMY as potential...
Via
Benzinga
Topics
ETFs
Government
Tourmaline Bio Stock Just Rocketed 58% Pre-Market – Here’s What Happened
September 09, 2025
Via
Stocktwits
Arrowhead Stock Rockets 11% Today – Retail Says $200M Upfront Payment From Novartis Collaboration Is ‘Hell Of A Deal’
September 02, 2025
Via
Stocktwits
How Is The Market Feeling About Novartis?
August 15, 2025
Via
Benzinga
Why Novartis' $1.4 Billion Takeover Of Tourmaline Bio Just 'Makes Sense'
September 09, 2025
Novartis agreed to buy a cardiovascular-focused biotech company
Via
Investor's Business Daily
Novartis Snaps Up Cardio-Focused Tourmaline Bio For $1.4 Billion
September 09, 2025
Tourmaline Bio shares skyrocketed Tuesday after Novartis agreed to buy the cardiovascular-focused biotech company.
Via
Investor's Business Daily
Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver
September 09, 2025
Novartis is betting big on radioligand cancer therapy, but while the long-term growth story looks strong, NVS stock may face a short-term pullback
Via
MarketBeat
Novartis To Expand Heart Drug Portfolio With $1.4 Billion Tourmaline Bio Acquisition
September 09, 2025
Novartis agreed to acquire Tourmaline Bio for $1.4 billion as pacibekitug shows strong trial results for inflammation and cardiovascular risk reduction.
Via
Benzinga
2024 R&D Spending and Intensity Benchmarks
September 08, 2025
Via
PRLog
Topics
Supply Chain
Novartis AG (NYSE:NVS) Offers a Compelling Mix of Dividend Yield, Profitability, and Financial Health
September 08, 2025
Discover Novartis (NVS), a top dividend stock with a strong 3.37% yield, high profitability, and a sustainable payout for reliable income.
Via
Chartmill
1 High-Yield Vanguard Dividend Fund to Buy Hand Over Fist
September 05, 2025
This international dividend powerhouse quietly delivered 26.6% returns this year -- more than doubling the S&P 500 while paying triple the income.
Via
The Motley Fool
Topics
ETFs
Stocks
Why Shares in Arrowhead Pharmaceuticals Surged on News of a Novartis Deal
September 05, 2025
The announcement of a landmark deal with a pharmaceutical giant validates Arrowhead's technology.
Via
The Motley Fool
Palantir Deepens Industry Ties As Lear And Lumen Embrace Its AI Platforms
September 04, 2025
Palantir is strengthening its role in the US industry through partnerships with Lear and Lumen and will showcase customer success stories at its AIPCon 8 event in September 2025.
Via
Benzinga
Topics
Artificial Intelligence
Palantir Hosts Eighth AIPCon. Stays Above 50-Day Line. Is PLTR Stock A Buy?
September 04, 2025
Palantir stock bulls tout the software maker's AI strategy and strong U.S. government business amid a lofty valuation for PLTR stock.
Via
Investor's Business Daily
Topics
Artificial Intelligence
ETFs
Government
Why Did Bollinger Innovations Stock Plunge 18% Today?
September 02, 2025
The company stated that it has eliminated third-party manufacturing, specifically with Roush Industries, and has instead consolidated the B4 production line from Roush Industries to the company-owned...
Via
Stocktwits
Arrowhead Pharma Jumps After Inking A Deal Worth Up To $2.2 Billion
September 02, 2025
Arrowhead Pharmaceuticals and Novartis inked a licensing deal Tuesday for an experimental Parkinson's drug.
Via
Investor's Business Daily
Gateway to Growth: Innovation and Opportunity at the 8th CIIE
September 01, 2025
Via
Press Release Distribution Service
Topics
Economy
Gateway to Growth: Innovation and Opportunity at the 8th CIIE
September 01, 2025
Via
Get News
Topics
Economy
Novo Nordisk Slowdown Weighs On Denmark's Economic Outlook
August 29, 2025
Novo Nordisk alone contributing one-fifth of employment gains to Denmark. But economic headwinds are mounting.
Via
Benzinga
Global Trade Braces for Impact: US-China Tariff Tensions Persist Amidst Fleeting Truces and Escalating Duties
August 28, 2025
The global economic landscape remains deeply entrenched in a complex and often volatile trade conflict between the United States and China. What began in January 2018 as a series of targeted duties has...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
FDA Eases Monitoring Burden For Kidney Disease Patients On Travere Therapeutics' Filspari
August 28, 2025
FDA eases REMS labeling for Travere's Filspari, reducing liver monitoring and removing embryo-fetal toxicity rules, with FSGS approval review ongoing.
Via
Benzinga
Powering Progress: AI's Insatiable Energy Appetite and Biotech's Dual Dawn
August 27, 2025
The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Emissions
UK Drug Pricing Talks Collapse, Drugmakers Reject Offer Citing 'Uncompetitive' System
August 22, 2025
UK drug pricing talks collapsed after the government and pharma firms failed to agree on National Health Service rebates.
Via
Benzinga
Novartis AG-Sponsored ADR (NYSE:NVS) – A Top Dividend Stock with Strong Yield and Financial Stability
August 18, 2025
Novartis (NVS) offers a strong 3.55% dividend yield, backed by consistent payouts, solid profitability, and financial health—ideal for stable income investing.
Via
Chartmill
Massive Headwinds Are on the Horizon for Pharmaceutical Stocks, but Here Are 2 That Could Weather the Storm
August 17, 2025
These companies have successfully navigated similar obstacles before.
Via
The Motley Fool
Topics
Intellectual Property
2 Dividend Stocks to Buy and Hold
August 15, 2025
These stocks look like they can weather almost any storm.
Via
The Motley Fool
Topics
Artificial Intelligence
Cannabis
Government
< Previous
1
2
3
4
5
6
7
8
9
...
48
49
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.